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Analysis of genetically engineered mice deﬁcient in cell cycle regulators, including E2F1,
cdk4, and pRB, showed that the major phenotypes are metabolic perturbations.These key
cell cycle regulators contribute to lipid synthesis, glucose production, insulin secretion,
and glycolytic metabolism. It has been shown that deregulation of these pathways can
lead to metabolic perturbations and related metabolic diseases, such as obesity and type
II diabetes. The cyclin–cdk–Rb–E2F1 pathway regulates adipogenesis in addition to its
well-described roles in cell cycle regulation and cancer. It was also shown that E2F1
directly participates in the regulation of pancreatic growth and function. Similarly, cyclin
D3, cdk4, and cdk9 are also adipogenic factors with strong effects on whole organism
metabolism. These examples support the emerging notion that cell cycle regulatory
proteins also modulate metabolic processes. These cell cycle regulators are activated
by insulin and glucose, even in non-proliferating cells. Most importantly, these cell cycle
regulators trigger the adaptive metabolic switch that normal and cancer cells require in
order to proliferate. These changes include increased lipid synthesis, decreased oxidative
metabolism, and increased glycolytic metabolism. In summary, these factors are essential
regulators of anabolic biosynthetic processes, blocking at the same time oxidative and
catabolic pathways, which is reminiscent of cancer cell metabolism.
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INTRODUCTION
Most physiological and pathological changes in cellular functions
are accompanied by an adapted metabolic switch. A regulated
cascade of molecular events senses external conditions and trig-
gers an adapted speciﬁc metabolic pathway. Each cell function,
such as proliferation, survival, growth, and senescence, requires
a speciﬁc adaptive metabolic response. Intermediary metabolism
must be coupled to the needs of the cell (e.g., growth, prolifer-
ation, and function); in other words, intermediary metabolism
must be coupled to either biosynthetic or oxidative metabolism.
Changes in cellular status that require metabolic adaptation can be
of physiological or pathological origin (Figure 1). As a general rule,
cell proliferation and clonal expansion, as observed during tissue
regeneration or developmental processes, create a strong demand
for carbon sources (glucose) for the synthesis of membranes,
organelles, and biomass. Glucose is also the source of energy and
redox equivalents. These needs are fully satisﬁed by anaerobic gly-
colysis and anabolic processes such as protein, nucleic acid, and
lipid biosynthesis. The preferential use of aerobic glycolysis offers
several advantages to highly proliferating cells, concerning both
bioenergetics and biosynthetic requirements. First, it allows for the
use of the most abundant extracellular nutrient, which is glucose.
Second, the ﬂux of adenosine triphosphate (ATP) can exceed that
produced during oxidative phosphorylation (OXPHOS). Third,
enzymes involved in lipid biosynthesis have been shown to sup-
port cancer cell proliferation (Bauer et al., 2005). This supports
the hypothesis that one of the critical roles of aerobic glycolysis is
to provide essential metabolic intermediates for the biosynthesis
of macromolecules (lipids, proteins, and nucleic acids) to support
increased proliferation.
Physiological conditions that are typically glycolytic include
vigorous anaerobic exercise. Under these conditions, high energy
levels are required to rapidly provide ATP for muscle contrac-
tion (Jensen and Richter, 2012). Similarly, pluripotent stem cells
present in adult tissues or during embryonic development rely
heavily on glycolysis for self-renewal to maintain pluripotency
(Zhang et al., 2011). Another physiological condition illustrat-
ing a glycolytic metabolic switch is T cell activation. During
this process, T cells undergo a metabolic reprograming from
oxidative metabolism in naïve cells to a glycolytic pathway in
activated cells (Wang et al., 2011). These are normal physiolog-
ical conditions that require changes in metabolism, but cells and
tissues adapt their metabolic pathways under pathological condi-
tions as well. A metabolic switch is also required to support the
shift from normal to pathological cell or tissue function. Many
pathologies, including diabetes, obesity, muscle disease, cardiac
hypertrophy, and cancer, can be identiﬁed by speciﬁc metabolic
changes. For example, hypertrophied hearts are characterized by
increased glycolysis and decreased oxidative metabolism com-
pared to normal hearts (Allard et al., 1994; Kolwicz and Tian,
2011). Strikingly, skeletal muscle of the mouse model and human
patients of Duchene’smuscular dystrophy exhibit decreasedoxida-
tive metabolism (Kuznetsov et al., 1998; Chen et al., 2000). Finally,
and most relevant for this review, we will discuss how cancer
cells switch their metabolism and what molecular mechanisms are
involved.
www.frontiersin.org January 2013 | Volume 3 | Article 4 | 1
“fonc-03-00004” — 2013/1/23 — 14:42 — page 2 — #2
Fajas Cell cycle metabolism
FIGURE 1 | Dual role of cell cycle regulators. In response to external
stimuli such as oncogenes, nutrition, or hormones, cell cycle regulators
trigger both a classical proliferative burst and an adapted metabolic
response (switch from oxidative to glycolytic), ultimately resulting in the
physiological or pathological condition.
Changes in cancer cellular metabolism have been thoroughly
reviewed elsewhere. It is well established that the process of can-
cer development and progression involves major alterations in
cellular metabolism. Similarly to physiological conditions that
demand large amounts of readily available energy, cancer cells are
highly glycolytic. One of the ﬁrst biochemical hallmarks of can-
cer cells to be identiﬁed was an alteration in metabolism. Early in
the last century, Otto Warburg (1928) observed that tumors have
a higher rate of glucose metabolism than normal tissues (War-
burg, 1930, 1956a,b). Since this ﬁrst observation, the “aerobic”
glycolysis switch has been detected in many tumor types, and
cumulating studies on various proliferating cells have demon-
strated evidence of a global metabolic change that takes place
during cancer progression. Most tumors are characterized by
higher rates of glycolysis, lactate production, and macromolecule
and lipid biosynthesis (Kroemer and Pouyssegur, 2008; Vander
Heiden et al., 2009). During aerobic glycolysis, glucose is converted
to pyruvate, and the ﬁnal product of this reaction is lactate, which
is exported out of the cell. Lactic acidosis is a typical complication
in cancer patients (Dhup et al., 2012). Although de novo fatty acid
(FA) synthesis is very active during embryogenesis, most adult
normal cells and tissues, even those with high cellular turnover,
preferentially use circulating FA for the synthesis of new struc-
tural lipids. In contrast, various tumors and their precursor lesions
undergo exacerbated endogenous FA biosynthesis irrespective of
the levels of extracellular lipids (Medes et al., 1953; Kuhajda, 2000;
Pizer et al., 2000).
The molecular mechanisms underlying the metabolic switch
observed in cancer cells are poorly understood. In addition to
triggering signaling cascades involved in proliferation and survival,
oncogenes (e.g., as ras, wnt, and AKT), cell cycle regulators (e.g.,
the cdk4–E2F1 axis), and some viral gene products also trigger
metabolic changes. Participation of these oncogenes in the inhibi-
tion of oxidative metabolism and increased glycolysis, which are
among the hallmarks of cancer, is well documented (Jones et al.,
2005; Shaw, 2006; Manning and Cantley, 2007; Wise et al., 2008;
Guo et al., 2011; Garcia-Cao et al., 2012). Coupling cellular func-
tion with the adapted metabolic response has to be controlled
by the same signaling network. Cell cycle regulators, notably the
cdk4–pRB–E2F1 axis, are the crucial factors in the control of cell
proliferation. It is therefore not surprising that they are also key
factors in metabolic control. Herein were view the relative partici-
pation of cell cycle regulators in the regulation of cell proliferation,
transformation, and metabolic control.
THE CLASSICAL ROLE OF CELL CYCLE REGULATORS:
PROLIFERATION AND SURVIVAL
Cyclins, cyclin-dependent kinases (cdks), transcription factor
E2F1, and retinoblastoma protein pRB are major regulators of
cell growth, development, and proliferation and are good candi-
dates as sensors of external signals that require a particular adapted
metabolic response. The most studied role of these factors is the
regulation of cell cycle progression in proliferating cells. Entry
into S-phase of the cell cycle depends on the activation of the G1
cyclins/cdks and the pRB–E2Fpathway that controls theG1/S tran-
sition of the cell cycle. Cdks are serine/threonine kinases that work
in complexes with different types of cyclins to phosphorylate the
retinoblastoma family of tumor suppressor proteins (pRB) medi-
ating the commitment of the cells to enter the cell cycle in response
to external stimuli (reviewed in Ortega et al., 2002). E2F transcrip-
tion factors are the effectors of this pathway, and they control the
expression of genes involved in cell cycle progression, apoptosis,
and DNA synthesis (for review, see Attwooll et al., 2004). E2Fs
regulate transcription through heterodimerization with members
of the DP family (DP-1 and DP-2; Dyson, 1998). When bound to
DNA, this heterodimeric complex exists as free E2F/DP or forms
a larger complex that contains a member of the retinoblastoma
protein family (pRB, p107, p130). E2F complexes can activate
(free heterodimers) or repress (large complexes) the transcription
of E2F-responsive genes. E2F activity is commonly increased in
many human cancers, including glioblastoma and lung, ovarian,
breast, stomach, and colon cancers (Chen et al., 2009), and much
evidence supports an oncogenic role for E2F1–3. It is clear that
the increased expression of E2Fs contributes to the uncontrolled
proliferation of cancer cells. We will discuss in this review the role
of the cdk–pRB–E2F axis as part of the control pathway of the
metabolic adaptive response triggered by growth factors.
THE NEW ROLE OF CELL CYCLE REGULATORS: METABOLIC
CONTROL
There is increasing evidence for a cdk4–E2F1–pRB-speciﬁc effect
inmetabolism. This includes a recent observation implicating pRB
in the control of oxidative metabolism in adipose tissue (Dali-
Youcef et al., 2007). In addition, we previously demonstrated that
cell cycle regulators participate in lipid metabolism. We showed
that E2Fs regulate adipogenesis by modulating the expression
of the nuclear receptor PPARγ, which is a master regulator of
adipogenesis (Fajas et al., 2002b). Similarly, we documented the
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adipogenic role of cyclin D3 (Sarruf et al., 2005), cdk4 (Abella
et al., 2005), and cdk9 (Iankova et al., 2006) through their positive
regulation of PPARγ activity. We also found that PPARγ activ-
ity and adipocyte differentiation are repressed by RB through the
recruitment of HDAC3 (Fajas et al., 2002a).
Analysis of genetically engineered mice deﬁcient for cell cycle
regulators, notably E2F1, cdk4, cyclin D3, p21, p19, and pRB,
show that the major phenotypes are metabolic perturbations. It is
shown that some of these cell cycle regulators are crucial factors in
metabolic control. Cdk4−/− and E2F1−/− mice have altered glu-
cose homeostasis and impaired mitochondrial function, reﬂecting
profound metabolic changes. In contrast, cdk4R24C mutant mice
with highly active cdk4 (almost constitutive) are obese (Aguilar
and Fajas, 2010). Interestingly, these metabolic changes are also
part of the metabolic switch observed in cancer, as discussed
below.
An example of the dual proliferation-metabolism regulatory
network is the regulation of cell physiology by insulin and glu-
cose. These factors stimulate proliferation of some cell types,
whereas they trigger a metabolic response in other cells, such as
pancreatic β-cells. Interestingly, cdk4 is activated by insulin in
pancreatic β-cells. Indeed, the cdk4–Rb–E2F network is a sensor
of the nutritional and energetic status of the cell, in particular
in pancreatic β-cells, where E2F1 regulates the expression of the
Kir6.2 gene, facilitating insulin secretion in these cells (Annicotte
et al., 2009). The cdk4–Rb–E2F pathway is also a negative regu-
lator of energy expenditure, through repression of mitochondrial
oxidative metabolism (Blanchet et al., 2011). Further support for
this hypothesis comes from genome-wide studies showing that a
cohort of genes involved inmitochondrial function are E2F targets,
indicating a potential role for E2Fs in linking the metabolic state of
the cell to cell cycle status (Cam et al., 2004). E2F1 transcriptional
activation of the pyruvate dehydrogenase kinase 4 (PDK4) gene,
a key nutrient sensor that is constitutively expressed in diabetes,
was also demonstrated to regulate glucose homeostasis in mus-
cle through inhibition of glucose oxidation (Hsieh et al., 2008). It
was shown that inactivation of pRB by the oncogenic E1A ade-
noviral protein also triggers PDK4 activity (Hsieh et al., 2008).
Increased E2F1 activity or inactivation of pRB therefore main-
tains high PDK4 expression and constitutively suppresses glucose
oxidation, such as observed in cancer. Furthermore, E2F1 stim-
ulates glycolytic ﬂux through regulation of the expression of the
phosphofructokinase 2 enzyme (Darville et al., 1995). In sum-
mary, these factors are essential regulators of anabolic biosynthetic
processes, blocking oxidative and catabolic pathways, which is
reminiscent of cancer cell metabolism (Figure 2).
E2F and pRB activities are regulated by cyclin/cdk complexes to
facilitate cell cycle entry and progression. It is therefore expected
that in the control of metabolism these holoenzymes also regu-
late metabolism. This is demonstrated by the analysis of cyclin
D-deﬁcient mice that show marked metabolic phenotypes, ﬁrst
observed in pancreas physiology. For instance, cyclin D2−/− mice
showed deregulated glucose homeostasis. This was the result of
decreased postnatal β-cell mass, glucose intolerance, and diabetes
(Georgia and Bhushan, 2004). Although cyclin D1+/− mice were
normal, life-threatening diabetes developed in 3-month-old cyclin
D1+/−D2−/− mice as β-cell mass decreased after birth (Kushner
FIGURE 2 | In normal tissue, cell cycle regulators control metabolic
processes, such as regulation of lipid synthesis, glycolysis, and
modulation of mitochondrial activity. Strikingly, these are the same
metabolic pathways that are deregulated in cancer cells.
et al., 2005). The conclusion from these studies was that cyclins
D2 and D1 were essential for β-cell expansion in adult mice. More
extensive analysis indicated that, in a glucose-stimulated insulin
secretion experiment, cyclin D2−/− mice demonstrated fasting
insulin levels similar to cyclin D2+/+ mice. Upon glucose stimu-
lation, cyclin D2−/− mice did not increase insulin levels, whereas
cyclin D2+/+ mice doubled their insulin secretion (Georgia and
Bhushan, 2004). This strongly suggests that, in addition to the
control of β-cell mass, cyclin D2 also participates in the control of
β-cell function. This is fully consistent with the function of E2F1
in these cells (Fajas et al., 2004; Annicotte et al., 2009).
Participation of cyclins in metabolism in not limited to the
control of pancreatic function. Cyclin D3-deﬁcient mice are pro-
tected from diet-induced obesity, exhibit reduced adipocyte size,
and exhibit increased sensitivity to insulin (Sarruf et al., 2005).
Cyclin D3 regulates adipose tissue mass through direct interaction
with PPARγ, the master regulator of adipogenesis. Another exam-
ple of metabolic control by cyclins includes the negative regulation
of oxidative metabolism by cyclin D1. Transgenic mice expressing
antisense cyclin D1 in the mammary gland of ErB2 mice showed
increased expression of genes that enhance oxidative glycolysis,
lipogenesis, and mitochondrial function (Sakamaki et al., 2006).
At odds with the metabolic cancer phenotype that shows increased
lipid synthesis is the observation that cyclin D1 inhibits lipogen-
esis in the liver in response to glucose stimulation. It was shown
that cyclin D1 inhibits the activity of the carbohydrate response
element-binding protein (ChREBP; Hanse et al., 2012). In con-
trast, it was shown in C. elegans that the cyclin D/cdk complex
regulates the expression of biosynthetic genes (Korzelius et al.,
2011). This effect may be limited to a particular physiological
condition in the liver and probably does not reﬂect pathological
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conditions, such as observed during carcinogenesis. Finally, in
support of a metabolic function of the cyclin D/cdk4 holoenzyme
in metabolism is the ﬁnding that some speciﬁc polymorphisms
in the cdk4 gene could contribute to type II diabetes-associated
obesity (Meenakshisundaram and Gragnoli, 2009a). Strikingly,
the same cdk4 IVS4-nt40 AA genotype is signiﬁcantly associated
with cancer in obese patients (Meenakshisundaram and Gragnoli,
2009b). In summary, cyclinDs/cdk4 regulates both cell growth and
metabolism, thus integrating both processes in cellular function
in normal and in transformed cells.
Other members of the cdk family also contribute to metabolic
control, such as cdk5. First, cdk5 is activated by glucose and insulin
in pancreatic β-cells (Lilja et al., 2001; Ubeda et al., 2004) and
adipocytes (Okada et al., 2008), respectively. Second, cdk5 par-
ticipates in the control of insulin secretion in β-cells (Lilja et al.,
2001). Third, cdk5 activity modulates the expression of a par-
ticular cluster of PPARγ genes in adipocytes, such as adiponectin,
leptin, and adipsin (Choi et al., 2010). Finally, a commonpolymor-
phism of the cdk5 regulatory unit CDKAL1 has been associated
with type II diabetes (Perry and Frayling, 2008). Similar to other
members of the cdk family, cdk5 also regulates cancer cell growth
and migration in glioblastoma (Liu et al., 2008), prostate cancer
(Strock et al., 2006), and pancreatic cancer (Feldmann et al., 2010),
among others. This further supports the hypothesis that the con-
trol of metabolic processes and cancer progression is not limited
to a single pathway but rather is a general and common way of
dual regulatory pathways.
The activities and functions of cyclin/cdk complexes are regu-
lated by the cdk inhibitors (CKIs). In line with our arguments, we
should also expect a metabolic function for these proteins. CKIs
comprise two families. The ﬁrst family includes the INK4 proteins
(for inhibitors of cdk4), which speciﬁcally bind and inhibit the
catalytic subunits of cdk4 and cdk6. The INK4 family includes the
four members p16INK4a, p15INK4b, p18INK4c, and p19INK4d,
and another unrelated protein designated as p19ARF. The sec-
ond family of CKIs is the Cip/Kip, which has a broad inhibitive
function, including inhibiting the activities of cyclins and CDKs.
This family includes p21Cip1, p27Kip1, and p57Kip2. Disruption
of CKI genes in the mouse has not revealed profound cell cycle
abnormalities, but does result in speciﬁc tumor and metabolic
phenotypes. Mice lacking p18INK4c are larger than wild-type
mice, a phenotype that varies with genetic background (Franklin
et al., 1998; Latres et al., 2000). This is consistent with the role
of p18INK4c as a cdk4 inhibitor, since cdk4-deﬁcient mice are
small. Similarly, disruption of p27Kip1 induces enhanced growth
of mice (Kiyokawa et al., 1996). Interestingly, it was demon-
strated that p27 and p21 are important regulators of adipogenesis,
and loss of either of these CKIs in genetically modiﬁed mouse
models induces adipocyte hyperplasia (Naaz et al., 2004). Fur-
thermore, combined deletion of p27 and p21 induces an increase
in adipocyte number, fat pad weights, and obesity in the dou-
ble knockout mice. Double knockout mice (p21−/−; p27−/−)
developed hypercholesterolemia, glucose intolerance, and insulin
insensitivity, which are metabolic adaptations of obesity (Naaz
et al., 2004). Genetic data fully support the participation of CKI
genes in metabolic pathways. The CDKN2A/B locus is associ-
ated with type II diabetes in several studies (Saxena et al., 2007;
Scott et al., 2007). The exact molecular mechanisms underlying
this association, however, are far from being elucidated.
Interestingly, mutations and polymorphisms in this locus are
also found in cancer, which reinforces the hypothesis that cell
cycle regulators play a dual role, regulating metabolic processes in
normal cells and regulating both proliferation and metabolism in
cancer cells (Hammerman et al., 2012; Sherr, 2012).
CONCLUSION
We have reviewed here studies showing that cell cycle regula-
tors control metabolic processes such as lipid synthesis, glycolysis,
and mitochondrial function, all of them being involved in the
metabolic switch required for cancer development and progres-
sion. This dual regulation, proliferation-metabolism, is a key
event for the successful viability of transformed cells. Inter-
ventions directed at uncoupling the metabolic response from
transformation signaling should impair cancer growth.
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